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Abstract
Background: Resistance to current chemotherapeutic agents is a major cause of therapy failure in ovarian cancer
patients, but the exact mechanisms leading to the development of drug resistance remain unclear.
Methods: To better understand mechanisms of drug resistance, and possibly identify novel targets for therapy, we
generated a series of drug resistant ovarian cancer cell lines through repeated exposure to three chemotherapeutic
drugs (cisplatin, doxorubicin, or paclitaxel), and identified changes in gene expression patterns using Illumina
whole-genome expression microarrays. Validation of selected genes was performed by RT-PCR and
immunoblotting. Pathway enrichment analysis using the KEGG, GO, and Reactome databases was performed to
identify pathways that may be important in each drug resistance phenotype.
Results: A total of 845 genes (p < 0.01) were found altered in at least one drug resistance phenotype when
compared to the parental, drug sensitive cell line. Focusing on each resistance phenotype individually, we
identified 460, 366, and 337 genes significantly altered in cells resistant to cisplatin, doxorubicin, and paclitaxel,
respectively. Of the 845 genes found altered, only 62 genes were simultaneously altered in all three resistance
phenotypes. Using pathway analysis, we found many pathways enriched for each resistance phenotype, but some
dominant pathways emerged. The dominant pathways included signaling from the cell surface and cell movement
for cisplatin resistance, proteasome regulation and steroid biosynthesis for doxorubicin resistance, and control of
translation and oxidative stress for paclitaxel resistance.
Conclusions: Ovarian cancer cells develop drug resistance through different pathways depending on the drug
used in the generation of chemoresistance. A better understanding of these mechanisms may lead to the
development of novel strategies to circumvent the problem of drug resistance.
Background
In the United States, ovarian cancer represents 3% of all
the new cancer cases in women, but accounts for 5% of
all the cancer deaths [1]. This discrepancy is due, in
part, to the common resistance of ovarian cancer to cur-
rent chemotherapy regimens. The vast majority of ovar-
ian cancer patients with advanced disease are treated
with surgery followed by adjuvant chemotherapy con-
sisting of a platinum agent (typically carboplatin) in
combination with a taxane (paclitaxel). Unfortunately,
while most patients initially respond to this combination
chemotherapy, a majority of the patients (up to 75%)
will eventually relapse within 18 months, many with
drug resistant disease [2]. The optimal management of
patients with recurrent tumors is unclear, especially for
drug resistant disease (by definition, a recurrence that
has occurred within 6 months of initial treatment), and
various studies have suggested different second line che-
motherapy approaches, all with limited success [3]. Ulti-
mately, the frequent development of drug resistance and
the lack of alternatives for the treatment of drug resis-
tant disease are responsible for a 5-year survival of
approximately 30% in ovarian cancer patients with
advanced disease. Indeed, 90% of the deaths from ovar-
ian cancer can be attributed to drug resistance [4].
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Studies have shown that ovarian cancer resistance is
multifactorial and may involve increased drug inactiva-
tion/efflux, increased DNA repair, alterations in cell
cycle control, and changes in apoptotic threshold. For
example, the copper transporter CTR1 has been shown
to mediate cisplatin uptake and cells with decreased
CTR1 exhibit increased resistance to cisplatin [5,6].
Another pathway, the PTEN-PI3K-AKT axis, has been
suggested to play an important role in the development
of drug resistance in several malignancies [7], including
ovarian cancer [8-10]. Overall, these studies indicate
that a better understanding of the mechanisms of drug
action and drug resistance may ultimately lead to new
approaches for circumventing resistance and improve
patient survival. However, in spite of recent advances,
the exact pathways important for the development of
drug resistance in ovarian cancer remain unclear. A bet-
ter understanding of the molecular mechanisms leading
to drug resistance may provide new opportunities for
the development of strategies for reversing or circum-
venting drug resistance [4,11].
In this manuscript, we generate novel drug resistant
ovarian cancer cell lines independently selected for resis-
tance to cisplatin, doxorubicin or paclitaxel, and we use
gene expression profiling to identify genes and pathways
that may be important to the development of drug resis-
tance in ovarian cancer.
Methods
Cell line and generation of drug resistance sub-lines
The ovarian cancer cell line OV90 was obtained from
The American Type Culture Collection (ATCC) and
grown in MCDB 105 (Sigma-Aldrich):Media 199 (Invi-
trogen) containing 15% bovine serum and antibiotics
(100 units/ml penicillin and 100 μg/ml streptomycin) at
37°C in a humidified atmosphere of 5% CO2. The che-
motherapeutic drugs cisplatin, doxorubicin, and pacli-
taxel were purchased from Sigma. The resistant sub-lines
were generated by exposure to the drugs for four to five
cycles. For each cycle, the cells were exposed to each
individual drug for twenty-four hours, and then trans-
ferred to normal media where they were allowed to grow
for 2 weeks. Following this two-week period, the cells
were re-exposed to the drug to initiate the next cycle.
Illumina Microarray and data analysis
RNA samples were purified using the RNeasy kit (Qia-
gen). Biotinylated cRNA was prepared using the Illu-
mina RNA Amplification Kit (Ambion, Inc.) according
to the manufacturer’s directions starting with approxi-
mately 500 ng total RNA. Hybridization to the Sentrix
HumanRef-8 Expression BeadChip (Illumina, Inc.),
washing and scanning were performed according to the
Illumina BeadStation 5006 manual (revision C). Array
data processing and analysis was performed using Illu-
mina Bead Studio software. Hierarchical clustering ana-
lysis of significant genes was done using an algorithm of
the JMP 6.0.0 software. Microarray analysis was per-
formed essentially as described [12]. Raw microarray
data were subjected to filtering and z-normalization.
Sample quality was assessed using scatterplots and gene
sample z-score-based hierarchical clustering. Expression
changes for individual genes were considered significant
if they met 4 criteria: z-ratio above 1.4 (or below -1.4
for down-regulated genes); false detection rate <0.30; p-
value of the pairwise t-test <0.05; and mean back-
ground-corrected signal intensity z-score in each com-
parison group is not negative. This approach provides a
good balance between sensitivity and specificity in the
identification of differentially expressed genes, avoiding
excessive representation of false positive and false nega-
tive regulation [13]. All the microarray data are MIAME
compliant and the raw data were deposited in Gene
Expression Omnibus database [GEO:GSE26465].
Real-time reverse transcription quantitative-PCR (RT-PCR)
Total RNA was extracted with Trizol (Invitrogen)
according to the manufacturer’s instructions. RNA was
quantified and assessed using the RNA 6000 Nano Kit
in the 2100 Bioanalyzer (Agilent Technologies UK Ltd).
One μg of total RNA from each cell line was used to
generate cDNA using Taqman Reverse Transcription
Reagents (PE Applied Biosystems). The SYBR Green I
assay and the GeneAmp 7300 Sequence Detection Sys-
tem (PE Applied Biosystems) were used for detecting
real-time PCR products. The PCR cycling conditions
were as follows: 50°C, 2 min for AmpErase UNG incu-
bation; 95°C, 10 min for AmpliTaq Gold activation; and
40 cycles of melting (95°C, 15 sec) and annealing/exten-
sion (60°C for 1 min). PCR reactions for each template
were performed in duplicate in 96-well plates. The com-
parative CT method (PE Applied Biosystems) was used
to determine the relative expression in each sample
using GAPDH as normalization control. The PCR pri-
mer sequences are available from the authors.
Antibodies and Immunoblotting
All the antibodies used for this work were obtained
from commercial sources. Anti-ABCB1 was purchased
from GeneTex. Anti-SPOCK2 and anti-CCL26 were
obtained from R&D Systems. Anti-PRSS8 and anti-
MSMB were obtained from Novus Biologicals. Anti-
GAPDH was purchased from Abcam. Immunoblotting
was performed as previously described [14].
Pathway Analysis
We used WebGestalt version 2 (http://bioinfo.vanderbilt.
edu/webgestalt/) to test for the enrichment of any
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pathway/terms that may be related to the drug resis-
tance phenotypes. Two different databases (KEGG, and
GO) were analyzed using Webgestalt. Overrepresenta-
tion analysis was also performed using the Reactome
database [15]. Ingenuity Pathway Analysis software
(Ingenuity Systems) was used to identify and draw net-
works relevant to the pathways identified.
Statistical analysis
Statistical analysis was conducted using Student’s t-test.
A p-value of <0.05 was considered statistically
significant.
Results
Generation of drug resistant cell lines
The drug-sensitive OV90 ovarian cancer cell line was
used as a parental line to generate a series of drug
resistant cell lines through repeated cycles of drug expo-
sure followed by recovery periods. Using this approach,
we generated drug-resistant OV90 sublines through
exposure to cisplatin, doxorubicin, or paclitaxel. The
lines derived through exposure to cisplatin (OV90C-A,
OV90C-D), doxorubicin (OV90D-6, OV90D-7), and
paclitaxel (OV90P-3, OV90P-7) all exhibited significant
resistance to their corresponding drugs compared to the
parental OV90 cell (Figure 1A). When cross resistance
was investigated, we found that the cisplatin-derived
resistant lines (OV90C-A and OV90C-D) were not
cross-resistant to doxorubicin or paclitaxel. In contrast,
the doxorubicin-derived resistant cells (OV90D-6 and
OV90D-7) exhibited significant cross-resistance to pacli-
taxel, and the paclitaxel-derived resistant cells (OV90P-3
and OV90P-7) were resistant to both cisplatin and dox-
orubicin (Figure 1A).
Figure 1 Establishment of drug resistant cell lines and gene expression profiling. A. IC50 values for the various cell lines used in this study.
Thick outlined squares show resistance levels for the drug against which the corresponding cell lines were derived. White squares denote lack of
resistance, and light gray squares, moderate resistance. Dark gray indicates drug resistance over 10-fold compared to the parental OV90 line. B.
Multi-dimensional scaling plot indicating the cell lines used for the gene expression profiling analysis. Each of the two different resistant clones
obtained from the 3 different drugs were cultured and analyzed in duplicate. Two cultures were analyzed for the parental OV90 (OV90-1 and
OV90-2). C. Venn diagram representing the number of genes significantly altered in each type of drug resistance. A total of 68 genes were found
altered in all three types of resistance generated following exposure to cisplatin, doxorubicin, and paclitaxel.
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Microarray analysis of gene expression in drug resistant
ovarian cancer cell lines
To identify genes and pathways important in the devel-
opment of drug resistance, we performed gene expres-
sion profiling analysis on the OV90 drug sensitive cell
line and on the resistant cell lines using Illumina Sentrix
microarrays. For each of the resistance types (cisplatin,
doxorubicin, and paclitaxel) two independent sublines
were profiled in duplicate (two different cultures). The
raw data were deposited in the Gene Expression Omni-
bus database [GEO:GSE26465]. Multidimensional scal-
ing (MDS) analysis based on gene expression data
showed that the cell lines clustered according to the
drug used in generating the resistance (Figure 1B),
demonstrating that the selection for resistance to differ-
ent drugs led to overall different patterns of gene
expression changes. This suggested different mechan-
isms of resistance for the different drugs. Comparison of
gene expression between sensitive and resistant lines
revealed numerous genes differentially expressed. A
total of 845 genes (P < 0.05, FDR<0.3) were found
altered in at least one drug resistance phenotype (Addi-
tional File 1, Figure 1C). Looking at each resistance phe-
notype individually, 460, 366, and 337 genes were
significantly altered (p < 0.01) in the development of
resistance to cisplatin, doxorubicin, and paclitaxel,
respectively. We identified 18 genes simultaneously
elevated in all three drug resistant phenotypes and 44
were downregulated in all three (Figure 1C, Additional
File 2). Table 1 shows the top 20 most differentially
expressed genes (elevated or decreased) in each one of
the three resistance phenotypes. When examining the
downregulated genes, only CCL26 was found in the top
20 genes in all three resistance phenotypes. None of the
top 20 up-regulated genes was found in common
between all 3 resistant phenotypes. Interestingly, several
genes of the serine protease family (PRSS genes) were
differentially expressed, although the direction of change
was variable (for example, PRSS2 was elevated in doxor-
ubicin resistance, but decreased in paclitaxel resistant
cells).
Hierarchical clustering of the 845 genes significantly
altered in at least one condition was performed and is
shown in Figure 2A. The variability in the expression
patterns among the 3 resistant phenotypes suggested in
the Venn diagram (Figure 1C) was evident in the clus-
tering as well (Figure 2A). Clustering was also per-
formed for the genes significantly differentially altered
in resistant cell lines developed through cisplatin expo-
sure (Figure 2B), doxorubicin exposure, (Figure 2C) and
paclitaxel exposure (Figure 2D). Again, the heat maps
showed that the cell lines exhibited little overlap in gene
expression changes following the development of resis-
tance to the different drugs.
Table 1 Top 20 genes down- and up-regulated in each drug resistance phenotype
Down-regulated Up-Regulated
Cisplatin Doxorubicin Paclitaxel Cisplatin Doxorubicin Paclitaxel
CLCA1 APOE PRSS3 C20orf75 RPIB9 APOA1
CCL26 MSMB CCL26 WFS1 IL8 GAGE6
RFTN1 CCL26 PRSS2 GNG11 TXNIP XAGE1
TCN1 ANKRD38 PRSS1 MFGE8 ABCB1 SCRG1
SCARF2 CDH11 RHOU CEACAM6 PRSS2 GAGE7B
MAPK13 PRSS8 TCN1 MTMR11 PRSS3 ALB
LDHA APOC1 PRNP PSG11 GNG11 VSIG1
ECAT11 ITIH2 FKBP11 PAM CD96 REG4
SPP1 MAF MSMB NOS3 LPXN AFP
DDIT4L FABP5 LCP1 GAGE6 SGK FAM112B
APOE IGSF4 NNMT CLYBL MLLT11 RP1-32F7.2
SPOCK2 SOX21 MAF GAGE7B CFB ADH1A
NINJ2 NPC2 ECHDC2 SERPINE2 GADD45A NMU
THBS1 SCD ANKRD38 CECR5 MYH4 CTAG2
SOX21 MT1F WDR72 ADAM15 CXCL6 ADH1C
CD44 RRAGD CD9 DPYSL3 GABARAPL1 AMBP
RGS4 SPOCK2 MATN2 REG4 POU2F2 MMP1
DDIT4 RENBP RRAGD GALR2 PRSS1 PRTFDC1
IGF2 SPINT2 SERPIND1 TFF2 CYR61 GAGE5
GPC3 RFTN1 A2M EEF1A2 TNFRSF11B TSPAN12
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In order to validate the microarray results, we selected a
number of highly differentially expressed genes present in
Table 1 for validation by RT-PCR. Nineteen genes whose
expression patterns were confirmed by RT-PCR are shown
in Figure 3A,B. ABCB1 was found highly overexpressed,
with increases of over 1,000-fold in OV90D and OV90P
cells, while the increase in cisplatin-resistant OV90C cells
was approximately 15-fold (Figure 3A). Similarly XAGE1D
expression was also increased 1,000-fold in OV90P cells
compare to the OV90 cells. For the other genes analyzed,
such as the GAGE family genes, CD96, and VSIG1, the
expression levels were increased significantly in various
drug resistant cells. In addition, we validated several genes
found downregulated in drug resistance (Figure 3B).
CCL26 was found downregulated more than 200-fold in
all three resistant phenotypes compared to drug sensitive
cells. RHOU and MAF1 were decreased over 2,000-fold in
OV90-P cells. The other genes analyzed, SPOCK2, RFTN1,
PRSS8, MSMB, ECAT11, CDH26, CDH11, CD9, and
CD44 were all decreased to various levels in the drug resis-
tant cells.
As further validation, we investigated the protein expres-
sion levels of selected candidates by immunoblotting. We
found five genes whose protein level changed significantly
in the drug resistant cell lines (Figure 3C). Consistent with
our RT-PCR findings, the P-glycoprotein (encoded by
ABCB1), a well-studied protein which has been implicated
in multi-drug resistance, was found elevated in all three
drug-resistant cell lines, including OV90C, in spite of a
relatively small increase in mRNA levels observed in cis-
platin cell lines (Figure 3A). On the other hand, the
CCL26, PRSS8, and MSMB proteins were found to be sig-
nificantly decreased in all three drug resistant cell lines.
The SPOCK2 protein was only found decreased in the
paclitaxel resistant lines (OV90P).
Pathway analysis of drug resistance
In order to gain some insight into the possible mechan-
isms important in the development of resistance to
these drugs, we performed pathway analysis using the
genes that were found significantly differentially
expressed in each resistance phenotype. We analyzed
the KEGG, GO, and Reactome databases for enrichment
of any potential pathways/terms in the 3 different drug
resistant cell lines (Table 2). While many pathways were
found enriched in each resistance phenotypes, some
pathways emerged as consistently identified in the three
databases. For example, all the approaches identified
various cell surface pathways, including ECM-mediated
events as altered in cisplatin resistance. Changes in
genes such as LAMA3, LAMA5, LAMB1, COL17A1,
CD44, ITGA2, SDCBP, and GPC3 contributed to these
pathways. Ingenuity network analysis was used to iden-
tify the relationship between these genes, as well as pos-
sible interactions with other genes found altered in our
dataset (Figure 4A). In addition, pathways associated
with cell movement were also identified in multiple
databases as enriched in cisplatin-derived resistant lines.
Doxorubicin-derived resistance showed a very strong
enrichment for changes in pathways involved protea-
some degradation (with changes in proteasome genes
PSMB4, PSME2 , PSMD8 , PSMB7, PSME4, PSMD14,
PSMB2, PSMC5, PSMF1, PSMA5). The p-values for
enrichment indicated that this pathway was clearly
dominant compared to other pathways (Table 2). Net-
work analysis revealed a vast array of interactions and
suggested that many upstream pathways, including NF-
B, may be involved in regulating the proteasome genes
identified here (Figure 4B). Paclitaxel resistance exhib-
ited changes in pathways related to mRNA and protein
synthesis, and the genes affected included multiple ribo-
somal genes (RPS20, RPL26, RPL10A, RPL39, RPL7, and
RPL34) and translation factors (EIF4A2, EEF1D). Net-
work analysis shows the possible relationship of the
translation pathway with other pathways, including VHL
(Figure 4C). Pathways related to oxidative stress
(UGT1A6, MAOA, GPX3, and CYBA) and glycolysis
(ADH1A, HK1, ENO3, PFKP, HK2, and ADH1C) were
Figure 2 Genes differentially expressed following the
development of drug resistance. A. Heat map showing the
expression of all the significant genes analyzed using the Illumina
bead array (845 genes). Changes in gene expression for the 3
pairwise comparisons are included in this analysis (OV90C vs OV90,
OV90D vs OV90, and OV90P vs OV90). B. Heat map representing the
clustering of genes significantly altered in cisplatin-derived drug
resistance. C. Heat map representing the clustering of genes
significantly altered in doxorubicin-derived drug resistance. D. Heat
map representing the clustering of genes significantly altered in
paclitaxel-derived drug resistance.
Sherman-Baust et al. Journal of Ovarian Research 2011, 4:21
http://www.ovarianresearch.com/content/4/1/21
Page 5 of 11
also found as altered in paclitaxel-derived resistance.
Consistent with the fact that gene expression changes
were different between the various resistance pheno-
types, the dominant pathways were also different (Figure
5), and few pathways were found in common between
the various types of resistance (Table 2). When the 62
genes that are found in common between all three resis-
tance phenotypes (Figure 1C) were studied for pathway
enrichment, the only pathway found significantly overre-
presented was the regulation of fatty acid metabolism
and oxidation, which included the differentially-
expressed genes NCOA3, NCOA1, ACADM, and
ACADVL.
Discussion
Drug resistance remains a major obstacle in cancer ther-
apy and significant efforts have been directed at under-
standing the mechanisms leading to the development of
resistance. Gene expression profiling has played a key
role in providing us with important clues regarding
genes and pathways that may be affected in drug
resistance. Overall, the picture that has emerged is that
the drug resistance is a multifactorial process involving
mechanisms that are both drug- and tissue-dependent.
To address these issues in ovarian cancer, we have gen-
erated cell lines that are individually resistant to cispla-
tin, paclitaxel, or doxorubicin. The combination of a
platinum compound (cisplatin) and paclitaxel represent
the standard initial chemotherapy for ovarian cancer,
while doxorubicin has shown some promise in the treat-
ment of recurrent drug-resistant disease [16]. Various
studies have investigated drug resistance, but few have
compared the drug resistance mechanisms associated
with the development of resistance to different drugs.
We found that the gene expression changes associated
with the development of drug resistance was dependent
on the drug used (Figure 1B), but the individual lines
generated from a given drug were extremely similar to
each other. This suggests that while cell lines adopted
different mechanisms to develop resistance to different
drugs, a given drug and conditions seem to favor similar
pathways. Interestingly, the patterns of expression
Figure 3 Validation of selected differentially expressed genes. A. RT-PCR analysis of genes elevated in drug resistant cells. The y-axis
represents fold up-regulation in the different drug resistant cell lines over the parental OV90 cell line. B. RT-PCR analysis of genes decreased in
drug resistant cells. The y-axis represents the fold down-regulation of the different resistant cell lines compared to the parental OV90 cell line. C.
Immunoblot analysis of selected gene products identified by microarray and RT-PCR as altered in drug resistant cells.
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associated with cisplatin and doxorubicin resistance
were more similar to each other than they were to cell
lines developed through paclitaxel exposure (Figure 2A).
This is further supported by the observation that the
number of differentially expressed genes shared by cis-
platin and doxorubicin (149) was greater than the num-
ber of genes shared by cisplatin and paclitaxel (115) or
paclitaxel and doxorubicin (97) (Figure 1C). Doxorubicin
and paclitaxel resistance can both arise through a multi-
drug resistance (MDR)-type mechanism, which generally
results from overexpression of ATP Binding cassette
(ABC) transporters [17], while cisplatin resistance is not
believe to have a significant MDR component. On the
other hand, cisplatin and doxorubicin are both DNA-
damaging agents (albeit acting through different
mechanisms), while paclitaxel is a microtubule stabiliz-
ing agent. Our data suggest that the overall changes in
gene expression tend to reflect the drug target rather
than an association with the MDR phenotype.
Overall, relatively few genes were simultaneously
altered in the 3 drug resistance phenotypes studied: only
18 genes were elevated and 44 genes decreased. Many
of these genes were validated and shown to be differen-
tially expressed at the protein level (Figure 3C). Pathway
enrichment analysis of these genes revealed that the
most significantly enriched pathway was “fatty acid
metabolism and oxidation” (4 genes were part of this
pathway). Certain genes consistently downregulated in
all the drug resistant lines were particularly interesting.
In particular, MSMB was found highly downregulated in
drug resistant cells at both the mRNA and the protein
levels (Figure 3B,C). Interestingly, MSMB has been
found decreased in prostate cancer and has been sug-
gested to function through its ability to regulate apopto-
sis [18]. With this function in mind, it is intriguing that
we identified MSMB as one of the most downregulated
genes following the development of drug resistance for
all three drugs. These findings suggest that MSMB or
derivatives may be useful in sensitizing ovarian cancer
cells to chemotherapy. In particular, a small peptide
derived from the MSMB protein has been shown to
exhibit anti-tumor properties [19] and has been sug-
gested as a potential therapeutic agent in prostate can-
cer [20]. It will be interesting to determine whether this
peptide may be useful in reversing drug resistance in
ovarian cancer and we are currently investigating this
enticing possibility. RFTN1 is another gene consistently
downregulated in all three drug resistance phenotype
Table 2 Pathway analysis: Pathways/Terms found enriched in the indicated databases for each of the resistance
phenotype are shown.
KEGG (P < 0.001) GO (P < 0.1) Reactome (P < 5e-04)
Cisp Leukocyte transendothelial migration (P = 2.7e-
06)
cell-substrate adhesion (adjP = 0.0011) Nephrin interactions (P = 5.1e-05)
Focal adhesion (P = 4.76e-06) response to chemical stimulus (adjP = 0.0012) Recruitment of Proteins To Vesicles (P = 2.7e-
04)
ECM-receptor interaction (P = 0.0001) cellular component movement (adjP =
0.0015)
Activation of PPARA by Fatty Acid (P = 2.8e-
04)
Ribosome (P = 0.0001) homeostasis of number of cells (adjP =
0.0028)
Cell-Cell communication (P = 3.3e-04)
TGF-beta signaling pathway (P = 0.0001)
Dox Proteasome (P = 2.28e-09) regulation of ubiquitin-protein ligase Proteasomal cleavage/Cell cycle (P = 3.2e-06)
Chemokine signaling pathway (P = 7.16e-06) (mitosis) (adjP = 1.74e-05) Platelet activation/degranulation (P = 4.7e-06)
Steroid biosynthesis (P = 8.46e-06) Cholesterol biosynthesis (P = 1.5e-05)
Tight junction (P = 8.91e-06)
Oocyte meiosis (P = 1.79e-05)
Leukocyte transendothelial migration (P = 2.1e-
05)
Tax Melanogenesis (P = 4.87e-05) cellular response to oxidative stress (adjP =
0.08)
Platelet activation/degranulation(P = 7.7e-06)
Glycolysis/Gluconeogenesis (P = 0.0002) cellular amino acid metabolism (adjP =
0.0782)
Translation (P = 4.2e-04)
Tight junction (P = 0.0002) hexose metabolic process (adjP = 0.0782)
Leukocyte transendothelial migration (P =
0.0005)
translation (adjP = 0.0782)
Glutathione metabolism (P = 0.0005)
Ribosome (P = 0.0006)
The p-values for each pathway are indicated.
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and it encodes a lipid raft protein. RFTN1 is located on
chromosome 3p24, a region shown to be frequently
deleted in ovarian cancer, including in OV90 cells [21].
This gene has also been shown to be mutated in some
ovarian tumors [22], suggesting that it may represent a
genuine tumor suppressor gene in this disease. Our
results suggest that it may also be involved in drug
resistance.
Multiple mechanisms can mediate the development of
drug resistance and include 1) changes in the regulation
or repair of the primary target of the drug (DNA,
microtubule, etc), 2) drug retention (increased influx or
decreased uptake), 3) increased drug inactivation or
sequestration, 4) signaling pathways that affect survival.
For cisplatin, copper transporter CTR1 has been shown
to play a crucial role in cisplatin uptake and knockout
of the CTR1 alleles can lead to resistance to cisplatin
toxicity [5]. On the other hand, paclitaxel and doxorubi-
cin are known substrates for the ATP-dependent efflux
pump P-glycoprotein (MDR transporter system, ABCB1)
and up-regulation of MDR1 has been associated with
clinical drug resistance in multiple systems [23]. While
Figure 4 Network of genes identified using Ingenuity Pathway Analysis. A. Network including ECM and other genes altered in cisplatin
derived resistant cells. B. Network including proteasome genes and other genes altered in doxorubicin resistant cells. C. Network containing
translation genes as well as other genes differentially expressed in paclitaxel-derived drug-resistant cells
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we failed to observe changes in the expression of CTR1
in cisplatin (or other) resistant lines, we did identify
MDR1 (ABCB1) as one of our most up-regulated genes
in all the resistant phenotypes, including cisplatin resis-
tant cells. Genes of the GAGE and MAGEA family have
also been found elevated in drug resistance. In particu-
lar, MAGEA3,6,11,12 as well as GAGE2,4,5,6 and 7 were
found elevated in ovarian cancer cells resistant to pacli-
taxel and doxorubicin [24]. In this study, we also find
GAGE5,6,7 and XAGE1 to be consistently elevated in
the various drug resistant lines, although the levels var-
ied according to the resistance phenotype.
While drug resistance development clearly involves
changes in a large number of genes and pathways, we
wondered whether pathway analysis may help us identify
“dominant” pathways for each drug resistance pheno-
type. Using pathway analysis, we were indeed able to
identify several dominant pathways altered in the differ-
ent drug resistant cells (Table 2 and Figure 4). Different
pathway databases identified different pathways, likely
because of variations in annotation and curation, but
comparison of the results from different databases
allowed us to find pathways that were consistently iden-
tified (Figure 4). In cisplatin-derived resistance, we fre-
quently found changes in ECM pathways altered. ECM-
Integrin interactions have previously been shown to
control cell survival [25] and ECM has been implicated
in ovarian cancer drug resistance [26] as well as lung
cancer drug resistance [27]. The development of doxor-
ubicin resistance exhibited strong changes in pathways
associated with proteasome degradation, This is particu-
larly interesting considering that bortezomib, a protea-
some inhibitor, has been found effective in combination
therapy with doxorubicin in several studies [28,29].
Because of the specific proteasome genes found altered,
as well as the presence of cell cycle genes differentially
expressed (such as CDK7), it is likely that the
proteasome pathway changes affect the cell cycle. It has
been shown that doxorubicin can affect G2/M transition
and cyclin B1 activity [30], and changes in the cell cycle
may therefore influence the response to doxorubicin
through changes in apoptosis sensitivity [31]. Paclitaxel
resistance was associated with changes in pathways
important for mRNA and protein synthesis, oxidative
stress and glycolysis. The exact mechanisms by which
these pathways can affect the resistance to paclitaxel
remain under investigation, but changes in apoptosis
sensitivity is a certain possibility since general mRNA
degradation and oxidative stress have been implicated in
apoptosis [32,33].
In conclusion, we have generated drug resistant ovar-
ian cancer cell lines through exposure to three differ-
ent chemotherapeutic drugs and identified gene
expression patterns altered during the development of
chemoresistance. Among the genes that are consis-
tently elevated we identify previously known genes
such as ABCB1 and genes of the MAGEA family.
Among the genes downregulated, we find genes such
as MSMB and PRSS family members that are impli-
cated for the first time in drug resistance. Overall, we
find that different drug resistance phenotypes have dif-
ferent expression patterns and we identify many novel
genes that may be important in the development of
cisplatin, doxorubicin and paclitaxel resistance. Path-
way analysis suggests enticing new mechanisms for the
development of resistance to cisplatin, doxorubicin,
and paclitaxel in ovarian cancer and we find that each
resistance phenotype is associated with specific path-
way alterations (Figure 5). Whether the identified path-
ways are causally related to drug resistance remains to
be determined and it will be important to follow up
these findings with mechanistic studies to better
understand the roles of the genes and pathways we
have identified.
Figure 5 Model for the development of various resistance phenotypes in ovarian cancer. Following selection for drug resistance with the
indicated drugs, a number of molecular pathways are altered. The molecular pathways identified as altered in the different conditions may be
functionally related to the development of drug resistance.
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Additional material
Additional file 1: Genes differentially expressed between sensitive
and resistant cell lines. The table lists the 845 genes significantly
altered in the drug resistant cell lines. The fold change is indicated for
each gene in each resistance phenotype (cisplatin, doxorubicin, and
paclitaxel).
Additional file 2: Genes simultaneously elevated in all three drug
resistant phenotypes. The table lists all 45 genes simultaneously altered
in all three resistance phenotypes (cisplatin, doxorubicin, and paclitaxel),
and the fold change is indicated for each.
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